Key result
Adipose stromal cells target metabolic syndrome by improving insulin resistance, inflammation, and lipids.
Why the study?
Although ADMSCs show therapeutic potential in preclinical studies of MetS, their efficacy is substantially influenced and impaired by the diseased local microenvironment.
While ADMSCs offer promising regenerative potential for metabolic syndrome, their therapeutic efficacy is significantly limited by the disease's pathological microenvironment, necessitating microenvironment-oriented strategies.
Should not change metabolic syndrome management; leaves open microenvironment-modifying strategies for adipose-derived mesenchymal stromal cell therapy.
Metabolic syndrome (MetS) is a complex metabolic disorder characterized by insulin resistance, central obesity, dyslipidemia, hypertension, and chronic inflammation, which collectively increase the risk of type 2 diabetes mellitus, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease. Although adipose-derived mesenchymal stromal cells (ADMSCs) have shown promising therapeutic potential in preclinical studies, their efficacy is substantially influenced by the diseased local microenvironment. Accumulating evidence indicates that ADMSCs exert multi-target therapeutic effects in MetS by alleviating insulin resistance, modulating inflammation, restoring mitochondrial and redox homeostasis, regulating lipid metabolism, and protecting vascular and metabolic organ function. However, the pathological state associated with MetS, characterized by chronic inflammation, oxidative stress, and metabolic imbalance, can reciprocally impair ADMSC function and limit their therapeutic efficacy. In this review, we summarize the current mechanistic understanding of ADMSC-based therapy for MetS and highlight the bidirectional interaction between ADMSCs and the local microenvironment network, discussing how exosome-based and microenvironment-oriented strategies may support the development of more precise and effective regenerative interventions for metabolic disease.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) conducted a review in Metabolic syndrome. Adipose-derived mesenchymal stromal cells (ADMSCs) was evaluated. Adipose-derived mesenchymal stromal cells exert multi-target therapeutic effects in metabolic syndrome by alleviating insulin resistance, modulating inflammation, and regulating lipid metabolism, though their efficacy is influenced by the diseased local microenvironment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: